Measurement of plasma glutathione S-transferase in hepatocellular damage in pre-eclampsia

KUMTEPE Y., BÖREKÇİ B., Aksoy H., Altinkaynak K., Ingec M., Ozdiller O.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, cilt.30, sa.5, ss.483-487, 2002 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 5
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1177/147323000203000503
  • Dergi Adı: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.483-487
  • Anahtar Kelimeler: pregnancy, pre-eclampsia, glutathione S-transferase (GST), hepatocellular damage, HELLP-SYNDROME HEMOLYSIS, ELEVATED LIVER-ENZYMES, SENSITIVE MARKER, LOW PLATELETS, ALPHA, PREECLAMPSIA, PREGNANCY
  • Atatürk Üniversitesi Adresli: Evet

Özet

Glutathione S-transferase (GST) is a cytosolic enzyme found in high concentrations in the liver. We investigated the value of plasma GST measurements in pre-eclamptic patients. A total of 80 patients (40 in the pre-eclampsia group and 40 in the control group) were recruited. All patients were evaluated for GST, alanine aminotransferase (ALT), aspartate aminotransferase and lactate dehydrogenase. Pre-eclampsia was defined as the occurrence, after 20 weeks' gestation, of a diastolic blood pressure greater than 90 mmHg on two or more occasions at least 4 h apart, and concomitant proteinuria greater than 0.3 g/l over a 24-h urine collection period. There was no statistical difference between the pre-eclampsia and control groups in terms of ALT, gestational age, maternal age or number of previous pregnancies; a significant difference was found between the pre-eclampsia and control groups in terms of GST. Preeclampsia represents a significant cause of maternal and perinatal morbidity and mortality. Accurate assessment of hepatocellular damage is essential in the clinical management of these patients. GST levels in pre-eclamptic patients were found to be much higher (131.98 IU/l) than in control patients (68.67 IU/l), and this high level suggests hepatocellular damage. We concluded that measurement of plasma GST might provide an earlier and much more sensitive indicator of hepatocellular damage than other liver-function tests.